Hannelore I. Bax

TL;DR: In this article, the authors reviewed the in vitro activities of these new antibiotics, especially against ESBL and CPE microorganisms, potential side effects, and clinical studies in complicated urinary tract infection (cUTI), intra-abdominal infections (cIAI), and hospital-acquired pneumonia/ventilator-associatedpneumonia (HAP/VAP).

TL;DR: In the past 20 years, nine antibiotic drugs with predominant activity against Gram-positive bacteria have been introduced and approved by the Food and Drug Administration or the European Medicines Agency.

TL;DR: The in vitro time kill-kinetics assay provides important information on the mycobacterial killing dynamics of anti-tuberculosis drugs during the early phase of drug exposure, and is a valuable component of the preclinical modeling framework.

TL;DR: A new design for treatment outcome evaluation in a mouse TB model is provided, which provides accurate tools for assessment of the relationship between treatment length and predicted cure, allows for efficient comparison between regimens and adheres to the reduction and refinement principles of laboratory animal use.

TL;DR: The data advocate the use of multiple mycobacterial strains, including a Beijing strain, to increase the translational value of mouse TB models evaluating treatment outcome, and support the notion that bactericidal activity in the first 2 months of treatment, as measured in clinical phase IIa/b trials, has limited predictive value for tuberculosis treatment outcome.